Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings is a research paper (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5K08CA245209-04
Fields of Study
Keywords